PL3280423T3 - Kompozycje i sposoby do synergistycznego leczenia glikokaliksu - Google Patents

Kompozycje i sposoby do synergistycznego leczenia glikokaliksu

Info

Publication number
PL3280423T3
PL3280423T3 PL16777402.5T PL16777402T PL3280423T3 PL 3280423 T3 PL3280423 T3 PL 3280423T3 PL 16777402 T PL16777402 T PL 16777402T PL 3280423 T3 PL3280423 T3 PL 3280423T3
Authority
PL
Poland
Prior art keywords
glycocalyx
compositions
methods
synergistic treatment
synergistic
Prior art date
Application number
PL16777402.5T
Other languages
English (en)
Inventor
Robert Maxfield LONG
Hans Vink
Original Assignee
Microvascular Health Solutions, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3280423(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Microvascular Health Solutions, LLC filed Critical Microvascular Health Solutions, LLC
Publication of PL3280423T3 publication Critical patent/PL3280423T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16777402.5T 2015-04-08 2016-04-08 Kompozycje i sposoby do synergistycznego leczenia glikokaliksu PL3280423T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562144484P 2015-04-08 2015-04-08
PCT/US2016/026739 WO2016164787A2 (en) 2015-04-08 2016-04-08 Synergistic glycocalyx treatment compositions and methods

Publications (1)

Publication Number Publication Date
PL3280423T3 true PL3280423T3 (pl) 2023-12-27

Family

ID=57072731

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16777402.5T PL3280423T3 (pl) 2015-04-08 2016-04-08 Kompozycje i sposoby do synergistycznego leczenia glikokaliksu

Country Status (14)

Country Link
US (2) US9943572B2 (pl)
EP (2) EP3280423B1 (pl)
JP (1) JP6518796B2 (pl)
KR (1) KR101972691B1 (pl)
CN (1) CN107771080B (pl)
AU (1) AU2016245994A1 (pl)
BR (1) BR112017021559A2 (pl)
CA (1) CA3020277A1 (pl)
DK (1) DK3280423T3 (pl)
ES (1) ES2954984T3 (pl)
HR (1) HRP20231090T1 (pl)
MX (1) MX2017012967A (pl)
PL (1) PL3280423T3 (pl)
WO (1) WO2016164787A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176089A1 (en) 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2018208846A1 (en) * 2017-05-08 2018-11-15 Microvascular Health Solutions, LLC Compositions, systems, and methods for assessing and improving vascular health and treatments involving the same
CN115778980A (zh) * 2017-12-14 2023-03-14 卡尔罗伊健康科学公司 通过硫酸化多糖稳定并逆转动脉粥样硬化病变的方法
MX2021013515A (es) * 2019-05-16 2022-01-04 Exthera Medical Corp Metodo para modular la estructura del glucocaliz endotelial.
WO2022182968A1 (en) * 2021-02-25 2022-09-01 Calroy Health Sciences, Llc Synergistic compositions and methods to increase vascular nitric oxide to treat endothelial dysfunction and related conditions
CN113476461A (zh) * 2021-08-23 2021-10-08 苏州大学 一种提高抑炎型巨噬细胞趋化的药物及其应用
WO2023023994A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种提高抑炎型巨噬细胞趋化的药物及其应用
KR20240060975A (ko) * 2022-10-31 2024-05-08 재단법인 오송첨단의료산업진흥재단 재조합 sod3 단백질의 생산 방법
WO2025049608A1 (en) * 2023-08-28 2025-03-06 Calroyhealth Sciences, Llc Compositions and methods to protect and enhance structural and functional integrity of the intestinal glycocalyx

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141181A1 (en) * 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US7214666B1 (en) * 1999-11-02 2007-05-08 Shawn Paul Madere Composition of orally administered nutritional supplements to repair articular cartilage
US6797705B2 (en) 2002-12-16 2004-09-28 Endomatrix, Inc. Rhamnan sulphate composition for treatment of endothelial dysfunction
EP2215480B1 (en) 2007-11-30 2012-04-18 Universiteit Maastricht Diagnostic and therapeutic tools for diseases altering vascular function
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
EP2323638B1 (en) 2008-07-18 2014-05-07 Hill's Pet Nutrition, Inc. Compositions and methods for treating osteoarthritis
WO2010109736A1 (ja) * 2009-03-25 2010-09-30 国立大学法人鳥取大学 軟骨生成促進剤および軟骨損傷由来疾病の予防治療剤
CA2701378C (en) * 2010-04-22 2022-11-01 Gina Athwal Seaweed-derived cosmetic compositions
US20140044797A1 (en) * 2011-04-19 2014-02-13 Rigshospitalet Prostacyclin and analogs thereof administered during surgery for prevention and treatment of capillary leakage
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients

Also Published As

Publication number Publication date
US9943572B2 (en) 2018-04-17
WO2016164787A3 (en) 2016-11-10
WO2016164787A2 (en) 2016-10-13
KR20170132886A (ko) 2017-12-04
EP3280423A4 (en) 2018-11-21
CN107771080A (zh) 2018-03-06
JP2018510906A (ja) 2018-04-19
MX2017012967A (es) 2018-06-06
BR112017021559A2 (pt) 2018-07-03
ES2954984T3 (es) 2023-11-28
EP3280423A2 (en) 2018-02-14
CA3020277A1 (en) 2016-10-13
EP4275704A3 (en) 2023-12-27
EP3280423B1 (en) 2023-06-07
JP6518796B2 (ja) 2019-05-22
CN107771080B (zh) 2021-12-14
DK3280423T3 (da) 2023-09-04
US20180078618A1 (en) 2018-03-22
EP4275704A2 (en) 2023-11-15
US20160296603A1 (en) 2016-10-13
KR101972691B1 (ko) 2019-04-25
HRP20231090T1 (hr) 2024-01-05
AU2016245994A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
IL259795A (en) Methods and compositions for treating a serpinc1-associated disorder
IL257105A (en) Modified cells and methods of therapy
IL257784A (en) Pharmaceutical composition used for reducing localised fat and use of pharmaceutical composition
IL280863A (en) Autotaxin inhibitors and uses thereof
KR20180084891A (ko) 구조 조성물 및 방법
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PL3280423T3 (pl) Kompozycje i sposoby do synergistycznego leczenia glikokaliksu
IL263439A (en) Composition and method for reducing neutropenia
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
SI3200815T1 (sl) Postopki in sestavki za zdravljenje raka
SI3189074T1 (sl) Sestavki in postopki za zdravljenje in preprečevanje vnetja
DK3324932T3 (da) Sammensætninger og fremgangsmåder for nanopartikel lyofile former
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
PT3261437T (pt) Compostos e composições fungicidas
DK3302478T3 (da) Pac-1 kombinations behandling
IL261010A (en) Preparations and methods for the treatment of chronic wounds
DK3240821T3 (da) Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde
PL3444349T3 (pl) Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach
PL3373922T3 (pl) Kompozycje i sposoby do stosowania do leczenia homocystynurii
DK3357520T3 (da) Viskoelastisk sammensætning
EP3349748A4 (en) COMPOSITION AND METHOD THEREFOR
DK3288536T3 (da) Sammensætninger omfattende anakinra